New insights and candidate genes and their implications for care of patients with hereditary prostate cancer

Current Urology Reports

Volumn 1, Issue 1, 2000, Pages 9-14

  Kim, Hyung L ^a   Steinberg, Gary D ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Androgen Receptor; Develop Prostate Cancer; Prostate Cancer; Radical Prostatectomy; Tate Cancer

Indexed keywords

CASE CONTROL STUDY; COHORT ANALYSIS; GENETICS; HUMAN; MALE; PROSTATE TUMOR; REVIEW; RISK FACTOR;

CASE-CONTROL STUDIES; COHORT STUDIES; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0034191012     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-000-0029-x     Document Type: Article

References (50)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 1999, 49:8–31. This is an up-to-date summary of cancer frequency, incidence, mortality, and survival.
2. Harlan L, Brawley O, Pommerenke F, et al.: Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol 1995, 13:93–100.
3. Ghadirian P, Howe GR, Hislop TG, Maisonneuve P: Family history of prostate cancer: a multi-center case-control study in Canada. Int J Cancer 1997, 70:679–681. DOI: 10.1002/(SICI)1097-0215(19970317)70:6<679::AID-IJC9>3.0.CO;2-S
4. Steinberg GD, Carter BS, Beaty TH, et al.: Family history and the risk of prostate cancer. Prostate 1990, 17:337–347. DOI: 10.1002/pros.2990170409
5. Keetch DW, Rice JP, Suarez BK, Catalona WJ: Familial aspects of prostate cancer: a case control study. J Urol 1995, 154:2100–2102. DOI: 10.1016/S0022-5347(01)66705-3
6. Lesko SM, Rosenberg L, Shapiro S: Family history and prostate cancer risk. Am J Epidemiol 1996, 144:1041–1047.
7. Monroe KR, Yu MC, Kolonel LN, et al.: Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med 1995, 1:827–829. DOI: 10.1038/nm0895-827
8. Fincham SM, Hill GB, Hanson J, Wijayasinghe C: Epidemiology of prostatic cancer: a case-control study. Prostate 1990, 17:189–206. DOI: 10.1002/pros.2990170303
9. Grönberg H, Damber L, Damber JE: Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer 1996, 77:138–143. DOI: 10.1002/(SICI)1097-0142(19960101)77:1<138::AID-CNCR23>3.0.CO;2-5
10. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH: Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994, 86:1600–1608. DOI: 10.1093/jnci/86.21.1600
11. Gronberg H, Damber L, Damber JE: Studies of genetic factors in prostate cancer in a twin population. J Urol 1994, 152:1484–1489.
12. Page WF, Braun MM, Partin AW, et al.: Heredity and prostate cancer: a study of World War II veteran twins. Prostate 1997, 33:240–245. DOI: 10.1002/(SICI)1097-0045(19971201)33:4<240::AID-PROS3>3.0.CO;2-L
13. Carter BS, Beaty TH, Steinberg GD, et al.: Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 1992, 89:3367–3371. DOI: 10.1073/pnas.89.8.3367
14. Gronberg H, Damber L, Damber JE, Iselius L: Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol 1997, 146:552–557.
15. Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN: Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998, 62:1425–1438. This is an example of how segregation studies were used to identify an autosomal dominant mode of transmission of a susceptibility gene for prostate cancer. DOI: 10.1086/301862
16. Gronberg H, Wiklund F, Damber JE: Age specific risks of familial prostate carcinoma: a basis for screening recommendations in high risk populations. Cancer 1999, 86:477–483. DOI: 10.1002/(SICI)1097-0142(19990801)86:3<477::AID-CNCR16>3.0.CO;2-K
17. Keetch DW, Humphrey PA, Smith DS, et al.: Clinical and pathological features of hereditary prostate cancer. J Urol 1996, 155:1841–1843. DOI: 10.1016/S0022-5347(01)66024-5
18. Bastacky SI, Wojno KJ, Walsh PC, et al.: Pathological features of hereditary prostate cancer. J Urol 1995, 153:987–992. DOI: 10.1016/S0022-5347(01)67619-5
19. Bauer JJ, Srivastava S, Connelly RR, et al.: Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. Urology 1998, 51:970–976. This study compares prognostic variables in familial and sporadic prostate cancer. DOI: 10.1016/S0090-4295(98)00103-4
20. Kupelian PA, Klein EA, Witte JS, et al.: Familial prostate cancer: a different disease? J Urol 1997, 158:2197–2201. DOI: 10.1016/S0022-5347(01)68194-1
21. Kupelian PA, Kupelian VA, Witte JS, et al.: Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. J Clin Oncol 1997, 15:1478–1480.
22. Bova GS, Partin AW, Isaacs SD, et al.: Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol 1998, 160:660–663. DOI: 10.1016/S0022-5347(01)62748-4
23. Grönberg H, Damber L, Tavelin B, Damber JE: No difference in survival between sporadic, familial and hereditary prostate cancer. Br J Urol 1998, 82:564–567.
24. Thiessen EU: Concerning a familial association between breast cancer and both prostatic and uterine malignancies. Cancer 1974, 34:1102–1107. DOI: 10.1002/1097-0142(197410)34:4<1102::AID-CNCR2820340421>3.0.CO;2-5
25. Isaacs SD, Kiemeney LA, Baffoe-Bonnie A, et al.: Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst 1995, 87:991–996. DOI: 10.1093/jnci/87.13.991
26. Damber L, Gronberg H, Damber JE: Familial prostate cancer and possible associated malignancies: nation-wide register cohort study in Sweden. Int J Cancer 1998, 78:293–297. DOI: 10.1002/(SICI)1097-0215(19981029)78:3<293::AID-IJC5>3.0.CO;2-Q
27. Smith JR, Freije D, Carpten JD, et al.: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search [see comments]. Science 1996, 274:1371–1374. DOI: 10.1126/science.274.5291.1371
28. Gronberg H, Xu J, Smith JR, et al.: Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1 (published erratum appears in Cancer Res 1998, 58:3191). Cancer Res 1997, 57:4707–4709.
29. Gronberg H, Smith J, Emanuelsson M, et al.: In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer. Am J Hum Genet 1999, 65:134–140. DOI: 10.1086/302447
30. Cooney KA, McCarthy JD, Lange E, et al.: Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 1997, 89:955–959. DOI: 10.1093/jnci/89.13.955
31. Hsieh CL, Oakley-Girvan I, Gallagher RP, et al.: Re: prostate cancer susceptibility locus on chromosome 1q: a confirmatory study [letter; comment]. J Natl Cancer Inst 1997, 89:1893–1894. DOI: 10.1093/jnci/89.24.1893
32. Eeles RA, Durocher F, Edwards S, et al.: Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet 1998, 62:653–658. DOI: 10.1086/301745
33. McIndoe RA, Stanford JL, Gibbs M, et al.: Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Genet 1997, 61:347–353.
34. Thibodeau SN, Wang Z, Tester DJ, et al.: Linkage analysis at the HPC1 locus in hereditary prostate cancer families. A J Hum Genet 1997, Suppl 61:A297.
35. Berthon P, Valeri A, Cohen-Akenine A, et al.: Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998, 62:1416–1424. DOI: 10.1086/301879
36. Whittemore AS, Lin IG, Oakley-Girvan I, et al.: No evidence of linkage for chromosome 1q42.2-43 in prostate cancer [letter]. Am J Hum Genet 1999, 65:254–256. DOI: 10.1086/302457
37. Xu J, Meyers D, Freije D, et al.: Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998, 20:175–179. This is a good example of a recent linkage study. DOI: 10.1038/2477
38. Ingles SA, Ross RK, Yu MC, et al.: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Instit 1997, 89:166–170. This is a good example of an association study. The androgen receptor and the vitamin D receptor are the two most popular genes studied using a candidate gene approach. DOI: 10.1093/jnci/89.2.166
39. Stanford JL, Just JJ, Gibbs M, et al.: Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997, 57:1194–1198.
40. Irvine RA, Yu MC, Ross RK, Coetzee GA: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995, 55:1937–1940.
41. Coetzee GA, Ross RK: Re: Prostate cancer and the androgen receptor [letter]. J Natl Cancer Instit 1994, 86:872–873. DOI: 10.1093/jnci/86.11.872
42. Taylor JA, Hirvonen A, Watson M, et al.: Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996, 56:4108–4110.
43. Kibel AS, Isaacs SD, Isaacs WB, Bova GS: Vitamin D receptor polymorphisms and lethal prostate cancer. J Urol 1998, 160:1405–1409. DOI: 10.1016/S0022-5347(01)62550-3
44. Ingles SA, Coetzee GA, Ross RK, et al.: Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 1998, 58:1620–1623.
45. Wadelius M, Andersson AO, Johansson JE, et al.: Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999, 9:635–639.
46. Rebbeck TR, Jaffe JM, Walker AH, et al.: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 [published erratum appears in J Natl Cancer Inst 1999, 91(12):1082]. J Natl Cancer Inst 1998, 90:1225–1229. DOI: 10.1093/jnci/90.16.1225
47. Gao X, Zacharek A, Salkowski A, et al.: Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 1995, 55:1002–1005.
48. Sigurdsson S, Thorlacius S, Tomasson J, et al.: BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 1997, 75:758–761. DOI: 10.1007/s001090050162
49. Wilkens EP, Freije D, Xu J, et al.: No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. Prostate 1999, 39:280–284. DOI: 10.1002/(SICI)1097-0045(19990601)39:4<280::AID-PROS8>3.0.CO;2-F
50. Nastiuk KL, Mansukhani M, Terry MB, et al.: Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 1999, 40:172–177. DOI: 10.1002/(SICI)1097-0045(19990801)40:3<172::AID-PROS5>3.0.CO;2-R